Monday, December 30, 2019, 11:00 AM - Wednesday, December 30, 2020, 11:59 PM


AMA PRA Category 1 Credits™ (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)

The term biologic usually refers to the group of complex molecules, such as monoclonal antibodies and receptor fusion proteins, developed to target specific proteins implicated in a variety of immune-mediated diseases, including psoriasis and other cutaneous diseases. Biologic agents have transformed the treatment of psoriasis. This panel discussion focuses on mechanism of action (MOA) of these therapeutic agents and how MOA affects clinical decision-making.

1. Define biologic therapy;
2. Review the MOA of approved and emerging biologics for the treatment of moderate to severe psoriasis;
3. Review the MOA of approved and emerging biologics for the treatment of cutaneous diseases other than psoriasis;
4. Discuss how the MOA of biologic therapeutics may affect clinical decision-making in dermatologic practice.

There are no fees for participating in and receiving CME credit for this online and print activity.

This activity can be accessed by clicking here.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

The University of Cincinnati and Evolve Medical Education are both accredited by the ACCME to provide continuing medical education for physicians, and have collaborated to design and execute this activity.

For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Cincinnati College of Medicine has a conflict of interest policy that requires, all faculty, planning committee members, and other individuals who are in a position to control content, to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity.

To view noted relationships for Drs. Joel Cohen, Adan Friedman, Joel Gelfand, and Alan Menter, visit the faculty tab.

The staff of University of Cincinnati and Evolve Medical Education, have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for CME purposes only and is not meant to substitute for the independent medical judgment of a physician relative to the diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC or The University of Cincinnati, or any of the companies that provided commercial support for this activity.

The registration form for this activity is currently unavailable.

This educational activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs LLC, and Bausch Health US.